Seer to Participate in Upcoming November Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Seer (Nasdaq: SEER) announced that company management will participate in two investor conferences in November 2025: the UBS Global Healthcare Conference in Palm Beach Gardens, FL with 1x1 meetings on Wednesday, November 12, 2025, and the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York with a fireside chat on Thursday, November 20, 2025 at 4:00 p.m. ET. Live webcasts will be available on the company's investor site investor.seer.bio, and archived replays will be posted on the company website after each conference.
Details
News Market Reaction – SEER
On Oct 30, the first trading day after this news, SEER closed 0.45% above the previous close.
Data tracked by StockTitan Argus for the Oct 30 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced company management will be participating in the following investor conferences:
- UBS Global Healthcare Conference in Palm Beach Gardens, FL
Hosting 1x1 meetings on Wednesday, November 12th
- Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, NY
Fireside chat on Thursday, November 20th at 4:00 p.m. Eastern Time
Live webcasts of the sessions will be available on the Investor section of Seer’s website at investor.seer.bio. Archived replays will be available on the company’s website following the conference.
About Seer
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics—delivering insights with scale, speed, precision, and reproducibility previously unattainable by other proteomic methods. Seer’s Proteograph Product Suite uniquely integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to solve challenges conventional methods have failed to overcome. Traditional proteomic technologies have struggled with inconsistent data, limited throughput, and prohibitive complexity, but Seer’s robust and scalable workflow consistently reveals biological insights that others do not. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information about Seer’s differentiated approach and ongoing leadership in proteomics, visit www.seer.bio.
Media Contact:
Patrick Schmidt
pr@seer.bio
Investor Contact:
Carrie Mendivil
investor@seer.bio
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.